Showing results (231-240 of 315) with videos related to

Sort By:
Pageof 32
Frontiers in Immunology|October 24, 2018
Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic EffectsLei Wang, Ming Ni, Angela Hückelhoven-Krauss, et al.
Bone Marrow Transplantation|April 7, 2019
Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019Rafael F Duarte, Myriam Labopin, Peter Bader, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 22, 2018
Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation StudySalyka Sengsayadeth, Myriam Labopin, Ariane Boumendil, et al.
The Lancet. Oncology|September 11, 2012
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trialMartin Bornhäuser, Joachim Kienast, Rudolf Trenschel, et al.
Bone Marrow Transplantation|April 25, 2024
Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)Christian Niederwieser, Simona Iacobelli, Georg-Nikolaus Franke, et al.
Journal for Immunotherapy of Cancer|January 10, 2024
Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective studyOlaf Penack, Thomas Luft, Christophe Peczynski, et al.
Bone Marrow Transplantation|June 19, 2026
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)Anna Ossami Saidy, Ariane Boumendil, Peter Dreger, et al.
Blood|April 15, 2024
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trialMoritz Fürstenau, Adam Giza, Jonathan Weiss, et al.
Leukemia|April 15, 2020
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantationJuan Carlos Hernández-Boluda, Arturo Pereira, Nicolaus Kröger, et al.
Blood Advances|March 4, 2026
OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMTNicole Santoro, Jarl Eduard Mooyaart, Urban Novak, et al.
Pageof 32